Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Today, on 21 October 2024, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting 2024 (the "EGM"). Notice of the EGM and complete proposals for resolutions taken are available on the Company's investor website, https://investor.expres2ionbio.com.
Resolution on a directed issue of shares (equalization issue)
The EGM resolved, in accordance with the Board of Directors' proposal, on an issue of not more than 384,530 new shares with deviation from the shareholders' preferential rights. Through the share issue, the Company's share capital will increase by no more than SEK 42,725.555633. All shares in the directed issue have been subscribed for by, and allotted to, Vator Securities AB.
Resolution to amend the articles of association with respect to the limits of the number of shares
The EGM resolved, in accordance with the Board of Directors' proposal, to amend the articles of association whereby the limits regarding the number of shares (5 §) are changed to "The number of shares in the company shall not be less than 2,100,000 and not more than 8,400,000".
Resolution on a reverse share split
The EGM resolved, in accordance with the Board of Directors' proposal, on a reverse share split of the Company's shares in relation 1:40, whereby the number of shares in the Company is reduced by combining forty (40) shares into one (1) share. The Board of Directors shall be authorized to determine the record date for the reverse share split (to occur after the resolution has been registered with the Swedish Companies Registration Office) and to take all other measures required for implementing the consolidation.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
The information was sent for publication, through the agency of the contact persons set out below, at the time stated by the Company's news distributor, Cision, at the publication of this press release.